Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Autor:
Marco Lucchi, Lorena Costardi, Angelo Morelli, Domenico Viggiano, Angela De Palma, Filippo Tommaso Gallina, Michele Rusca, Giovanni Muriana, Silvia Ceccarelli, Andrea De Vico, Lorenzo Spaggiari, Giuseppe Marulli, Roberto Crisci, Angelo Carretta, Lorenzo Rosso, Enrico Ruffini, Paolo Mendogni, Francesco Puma, Luigi Ventura, Francesco Londero, Luca Bertolaccini, Edoardo Bottoni, Federico Rea, Marco Alloisio, Giuseppe Cardillo, Marco Schiavon, Maria Teresa Congedo, Nicola Tamburini, Pio Maniscalco, Giampiero Negri, Francesco Facciolo, Sara Ricciardi, Stefano Margaritora, Stefano Bongiolatti, Ilaria Ceccarelli, Luca Voltolini
Publikováno v:
Lung Cancer. 154:29-35
Backgrounds Oligometastatic Non-Small Cell Lung Cancer (NSCLC) patients represent a category without a standard therapeutic approach. However, in selected oligometastatic NSCLC, radical surgery seems to offer a good prognosis. This retrospective stud
Publikováno v:
Lung Cancer. 142:20-27
Objective The purpose of this study was to investigate the relationship between neighborhood environment and lung cancer outcomes among Florida residents younger than 65 years of age. Methods and materials This was a retrospective cohort study that i
Autor:
Toru Kumagai, Osamu Kanai, Kyoichi Okishio, Keisuke Aoe, Isamu Okamoto, Kayoko Kibata, Makiko Yomota, Junichi Shimizu, Hiroshi Tanaka, Daichi Fujimoto, Hiroshi Sakai, Young Hak Kim, Keiko Mizuno, Jun-ya Ueda, Takashi Haku, Yuichiro Ohe, Takeshi Masuda, Satoshi Oizumi, Ryo Morita, Hiroaki Tsukamoto, Makoto Nishio, Haruhiro Saito, Toshiyuki Kozuki, Hirotoshi Hoshiyama, Hiroyuki Suzuki, Osamu Hataji
Publikováno v:
Lung Cancer. 140:8-18
Objectives To describe the treatment patterns and determine the effectiveness and safety of nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan. Materials and methods Japanese patients with NSCLC who received niv
Publikováno v:
Lung Cancer. 137:123-128
Our study aimed to investigate the independent prognostic values of consolidation-to-tumor ratio (CTR) and tumor disappearance ratio (TDR) after adjustment for the conventional prognostic factors and the eighth edition clinical T category for patient
Autor:
Claudia Proto, Alessandro De Toma, Giuseppe Lo Russo, Nicoletta Zilembo, Marina Chiara Garassino, Benedetta Trevisan, Arsela Prelaj, Filippo Pagani, Giulia Galli, Roberto Ferrara, Monica Ganzinelli, Filippo de Braud, Giovanni Randon, Diego Signorelli
Publikováno v:
Lung Cancer. 137:38-42
Most trials with Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung Cancer (NSCLC) included only small subgroups of patients aged ≥65. As NSCLC is often diagnosed in patients aged ≥70, real-world data about efficacy and safety of immunot
Autor:
Simon Ekman, Fred R. Hirsch, Johan Botling, Johanna Sofia Margareta Mattsson, Linnea LaFleur, Georgios Tsakonas, Teresa Boyle, Christopher J. Rivard, Patrick Micke
Publikováno v:
Lung Cancer. 133:69-74
Background c-MET protein overexpression has been proposed as a biomarker in non-small cell lung cancer (NSCLC), albeit its role in the clinical setting has not been firmly established yet. Patients and methods: We designed a retrospective cohort stud
Autor:
Masatsugu Hamaji, Toyofumi F. Chen-Yoshikawa, Daisuke Nakajima, Toshi Menju, Yojiro Yutaka, Toshihiko Sato, Hiroshi Date, Makoto Sonobe, Akihiro Ohsumi, Atsushi Kawaguchi
Publikováno v:
Lung Cancer. 125:192-197
In high-risk operable geriatric patients undergoing palliative sublobar resection (SR), noncancerous comorbidities may contribute to unfavorable outcomes. The purpose of this retrospective study was to evaluate the perioperative safety and long-term
Autor:
Carlos Alvarez, Ana Belén Enguita, Julio Sánchez de Cos, Roldán Cortés, Luis Seijo, Cristina Balcells, Eduard Monsó, Esther Barreiro, Marta Cascante, Anabel Martinez-Romero, Ramon Rami-Porta, Laura Millares
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
instname
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients diagnosed in early stage and surgically-treated have five-year mortality rate >20%. The identification of biomarkers able to predict progression and death may help to identify patients needing
Autor:
Steven J. Feigenberg, Martin J. Edelman, Katherine A. Scilla, Vincent K. Lam, Josephine Feliciano, Pranshu Mohindra, Elizabeth Nichols, Melissa A.L. Vyfhuis, Søren M. Bentzen, Neha Bhooshan
Publikováno v:
Lung Cancer. 104:52-57
To determine the prognostic effect of Body Mass Index (BMI) in definitively treated locally advanced NSCLC patients.In this single institution retrospective cohort study, we evaluated 291 patients who were treated for locally advanced NSCLC from 2000
Publikováno v:
Lung Cancer. 104:91-97
Objectives The purpose of this study was to investigate the prognostic impact of tumor volume (TV) on patients with stage I non-small cell lung cancer (NSCLC) after complete resection. Materials and Methods We retrospectively reviewed the clinicopath